Brief: Xspray Q2 Revenue SEK 0
15/08/2025 07:00
Aug 15 (Reuters) - Xspray Q2 pretax profit SEK -44.885 million. Q2 adjusted EPS SEK -2.35 Q2 adjusted free cash flow SEK -44.111 million
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003